knowledge -WSS

knowledge

author：entertainment 2025-10-02 00:28:32 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Kaiser Permanente unions announce official strike date

hotspot

WSS

Artificial intelligence use in health care faces greater scrutiny in 2024

Congress might make insulin pumps more accessible to the blind

Latigo launches with $135 million for Vertex

Why do women spend more than men on medical expenses?

Juul documents reveal insider tactics on political lobbying

Artificial intelligence use in health care faces greater scrutiny in 2024

leisure time

knowledge

leisure time

Continuity nursing helped my family in our darkest PICU moments

Menendez indictment could see pharma lose a key ally

Sports medicine is finally prioritizing gender equality

Cigna to pay $172 million to settle Medicare Advantage fraud probe

How one medical school became remarkably diverse

WHO recommends dropping component of many flu vaccines

Trump demands the U.S. pay no more for drugs than other countries … again

Long Covid research funding gets a major boost from NIH

23andMe had bad news about my health. I wish a person had delivered it

FDA advisers vote against ALS treatment from BrainStorm

hotspot

Eli Lilly reports tirzepatide MASH success during Q4 earnings

How the Dana

Sudafed saga points to U.S. issues with evaluating older drugs

STAT Boddities: What happens to the brain when we get scared?

Data show record exodus of life scientists from academia

How the Dana

hotspot

entertainment

focus

hotspot